Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer

Surgery Today

Volumn 26, Issue 4, 1996, Pages 250-257

  Sonoo, Hiroshi ^a   Kurebayashi, Junichi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

breast cancer; CA 15 3; carcinoembryonic antigen; serum tumor marker; tissue polypeptide antigen

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY;

ADULT; AGED; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; SURVIVAL RATE; TISSUE POLYPEPTIDE ANTIGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0029928617     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00311583     Document Type: Article

References (30)

1. Chu TM, Nemoto T (1973) Evaluation of carcinoembryonic antigen in human mammary carcinoma. J Natl Cancer Inst 51:1119-1122
2. Steward AM, Nixon D, Zamcheck N, Aisenberg A (1974) Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 33:1246-1252
3. Tormey DC, Waalkes TP, Snyder JJ, Simon RM (1977) Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen. Cancer 39:2397-2404
4. Woo KB, Waalkes TP, Ahmann DL, Tormey DC, Gehrke CW, Oliverio VT (1978) A quantitative approach to determining disease response during therapy using multiple biologic markers. Cancer 41:1685-1703
5. Falkson HC, Van Der Watt JJ, Portugal MA, Pitout MJ, Falkson G (1978) Carcinoembryonic antigen in patients with breast cancer. An adjunctive tool to monitor response and therapy. Cancer 42:1308-1313
6. Haagensen DE, Kister SJ, Vandevoorde JP, Gates JB, Smart EK, Hansen HJ, Wells SA (1978) Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer 42:1512-1519
7. Myers RE, Sutherland DJ, Meakin JW, Kellen JA, Malkin DG, Markin A (1978) Carcinoembryonic antigen in breast cancer. Cancer 42:1520-1526
8. Haagensen DE Jr, Kister SJ, Panick J, Giannola J, Hansen HJ, Wells SA (1978) Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma. Cancer 42:1646-1652
9. Lokich JJ, Zamcheck N, Lowenstein M (1978) Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer. Ann Int Med 89:902-906
10. Haagensen DE Jr, Barry WF, Mccook TA, Giannola J, Ammirata S, Wells SA (1980) The value of serial plasma levels of carcinoembryonic antigen and gross cystic disease fluid protein in patients with breast carcinoma and osseous metastases. Ann Surg 5:599-603
11. Staab HJ, Ahlemann LM, Koch HL (1980) Serial CEA determination in the management of patients with breast cancer. Oncodevelop Biol Med 1:151-160
12. Silva JS, Leight GS, Haagensen DE Jr. Tallos PB, Cox EB, Dilley WG, Wells SA (1982) Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen. Cancer 49:1236-1242
13. Mughal AW, Hortobagyi GN, Pritsche HA, Buzdar AU, Yap HY, Blumenschein GR (1983) Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA 249:1881-1886
14. Waalkes TP, Enterline JP, Shaper JH, Abeloff MD, Ettinger DS (1984) Biological markers for breast carcinoma. Cancer 53:644-651
15. Beard DB, Haskell CM (1986) Carcinoembryonic antigen in breast cancer. Am J Med 80:241-245
16. Hayes DF, Zurawski VR, Kufe DW (1986) Comparison of circulating CA 15-3 and carcinoembryonic antigen in patients with breast cancer. J Clin Oncol 4:1542-1550
17. Pons-Anicet DMF, Krebs BP, Mira R, Namer M (1987) Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer 55:567-569
18. Tondini C, Hayes DF, Gelman R, Henderson TC, Kufe DW (1988) Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107-4112
19. Colomer R, Ruibal A, Salvador L (1989) Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64:1674-1681
20. Kiang DT, Greenberg LJ, Kennedy BJ (1990) Tumor marker kinetics in the monitoring of breast cancer. Cancer 65:193-199
21. Gion M, Mione R, Gatti C, Dittadi R, Leon A, Nascimben O, Pizzorno B, Bruscagnin G (1990) Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA 15-3 and MCA. Tumori 76:360-364
22. Jotti GS, Bombardieri E (1990) Circulating tumor markers in breast cancer. Anticancer Res 10:253-258
23. Frabcini G, Montagnani M, Petrioli R, Paffetti P, Marsili S, Leone V (1990) Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Int J Biol Markers 5:65-72
24. Barak M, Steiner M, Finkel B, Abrahamson J, Antal S, Gruener N (1990) CA 15-3, TPA and MCA as markers for breast cancer. Eur J Cancer 26:577-580
25. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L (1991) Evaluation of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64:154-158
26. O'Brien DP. Horgan PG, Gough DB, Skehill R, Grimes H, Given HF (1992) CA 15-3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl 74:9-11
27. Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ (1992) CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70:2831-2834
28. Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, Chang AYC (1986) Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 4:46-56
29. Hayward JL, Rubens RD, Carbone P, Heuson JC, Kumaoka S, Segaloff A (1977) Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva. Switzerland. Cancer 39:1289-1294
30. Kurebayashi J, Kurosumi M, Sonoo H (1995) A new human breast cancer cell line, KPL-1, secretes tumour-associated antigens and grows rapidly in female athymic nude mice. Br J Cancer 71:845-853